Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient, surgically resectable endometrial cancer.
MedPage Today on MSN2d
Better Response, Survival in Head and Neck Cancer With Dual Pre-Op ImmunotherapyTwo neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...
During a live event, Sumanta K. Pal, MD, discusses the efficacy and safety findings from the CheckMate 274 trial of adjuvant ...
CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...
Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...
PD-1 blockade conferred benefit to certain women with surgically resectable endometrial cancer, findings presented at Society ...
A recent study published in JAMA Oncology presents promising new data on a treatment regimen beneficial to patients with a ...
In the post hoc analysis, the benefit of adjuvant nivolumab was seen both in patients with MIBC who had previously received neoadjuvant chemotherapy and those who had not, and in patients with ...
Source Reference: Zdenkowski N, et al "Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61–20; Neo-N): a non-comparative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback